Prof Erba speaks with ecancertv at ASH 2016 about phase 1b trials of combining standard chemotherapy with a CD33 antibody-drug conjugate against acute myeloid leukaemia.

He describes the drug design, patient characteristics and response rates, including adverse events with a tendency towards low-grade nausea and diarrhoea, and considers the significant benefits to patient outcomes after a single round of treatment.

More detail is available through ecancer news here.

Prof Erba presented these results in a press conference, with video coverage available here, and these findings are reviewed by Dr Mikkael Sekeres here.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.